Key result
ARBs offer diverse therapeutic benefits beyond BP lowering to enable personalized treatment based on comorbidities.
Why the study?
Do different angiotensin receptor blockers (ARBs) offer distinct therapeutic benefits beyond blood pressure lowering in hypertensive patients with specific comorbidities?
Do different angiotensin receptor blockers (ARBs) offer distinct therapeutic benefits beyond blood pressure lowering in hypertensive patients with specific comorbidities?
This review highlights that individual ARBs possess distinct pharmacological properties and clinical benefits beyond blood pressure reduction, emphasizing the need for customized therapy based on patient comorbidities.
May guide comorbidity-based ARB selection in hypertension; leaves open head-to-head trials to confirm differential outcomes.
The renin-angiotensin-aldosterone system plays an important role in the pathophysiology of hypertension and is closely related with cardio- and cerebrovascular events and chronic kidney diseases. Each angiotensin receptor blocker (ARB) is important in the treatment of hypertension, according to the results of recent years. This is a practical review of the available evidence on the different benefits of ARBs beyond their blood pressure-lowering effect, with an emphasis on the differences found between the particular compounds and the therapeutic implications of the findings, with specific reference to the co-morbidities.
No takes yet. Share an insight, caveat, or question.
Csaba András Dézsi (2016) conducted a review in Hypertension and comorbidities. Angiotensin receptor blockers (ARBs) was evaluated. Angiotensin receptor blockers offer diverse therapeutic benefits beyond blood pressure lowering, allowing for personalized treatment choices based on specific patient comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: